LISS enables immune evasion of colorectal cancers irrespective of MSI status
Qingyu Lin, Xingwen Wang, Wei Zhao, Shiying Song, Yi Zhang, Jiangwen Ma, Tianyu Li, Yuhan Wei, Minqiao Lu, Guixue Hou, Meiqi Wang, Hao Liu, Shanliang Zheng, O.Yu. Burenina, Zhiyuan Xiang, Li Li, Jiaqi Zhu, Ying Hu
Paper details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026.5.26
- Citations
- 0
- References
- 46
- Fields
- Medicine, Biology
Abstract
Despite being hailed as a significant advancement in cancer treatment, immune checkpoint blockade (ICB) has not yielded favorable outcomes in colorectal cancer, both in approximately 85% of cases characterized by microsatellite stability (MSS) and approximately 50% of microsatellite instability (MSI) cases. How ICB efficiency in colorectal cancer treatment can be improved remains unclear. Here, we identify a new immunoregulatory long non-coding RNA (lncRNA) gene named lncRNA of IFN-γ-signaling suppressor (LISS). LISS expression is increased in colorectal cancers and is linked to poor prognosis, as well as a high CD8+ score. Functional studies reveal that LISS impairs T cell-mediated cytotoxicity, regardless of MSS/MSI status. Mechanistically, LISS interacts directly with the kinase regulatory domain in calmodulin-dependent kinase (CamK)IIγ through a microdomain containing two independent RNA stem-loops. This interaction prevents the binding and phosphorylation of its substrate signal transducer and activator of transcription1 (STAT1) at serine(S)727, a modification necessary for optimal activation of STAT1 and the subsequent major histocompatibility complex I (MHC-I) gene expression. Analysis of human colorectal cancer samples reveals significant inverse correlations between LISS and pS-STAT1 or MHC-I. The knock-in of LISS in intestinal epithelium promotes adenoma development in Apcmin/+ mice. LISS antisense oligonucleotide (ASO)-based therapies enhance the responses of both MSS and MSI colorectal cancers to ICB in vivo, mainly by restoring MHC-I expression. Therefore, we have identified the previously uncharacterized lncRNA LISS to be a regulator of T cell immunity. Targeting it may be an effective therapeutic strategy to improve ICB in colorectal cancers with varying MSI characteristics.
Citation format
LIN, Qingyu, et al. LISS enables immune evasion of colorectal cancers irrespective of MSI status. Signal Transduction and Targeted Therapy, 2026, 11(1).